Naba Alsaha Medical Services (9546) Fundamentals 2026 — P/E 16.0x, Revenue Analysis | SniperIQ
Naba Alsaha Medical Services (9546) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 441M, trading at SAR 21.00 on the SAU. This SniperIQ fundamentals page covers Naba Alsaha Medical Services's valuation (P/E 16.0x, P/B 2.0x), profitability (net margin 13.6%), revenue (SAR 202M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Naba Alsaha Medical Services's market cap?
Naba Alsaha Medical Services (9546) has a market capitalization of approximately SAR 441M, trading at SAR 21.00 on the SAU. Market cap moves with the live share price.
What is Naba Alsaha Medical Services's P/E ratio?
Naba Alsaha Medical Services's trailing twelve-month P/E ratio is 16.0x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Naba Alsaha Medical Services?
Naba Alsaha Medical Services runs a net profit margin of 13.6%, a gross margin of 32.8%, and an operating margin of 15.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Naba Alsaha Medical Services generate?
Naba Alsaha Medical Services reported revenue of SAR 202M for fiscal year 2025, with net income of SAR 28M and earnings per share (EPS) of 1.31. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Naba Alsaha Medical Services pay a dividend?
Naba Alsaha Medical Services does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Naba Alsaha Medical Services financially healthy?
Naba Alsaha Medical Services carries a debt-to-equity ratio of 0.55x and a current ratio of 6.26x, with a market beta of -0.41. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Naba Alsaha Medical Services a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Naba Alsaha Medical Services (9546) the key facts are: market cap SAR 441M, P/E 16.0x, revenue SAR 202M, 52-week range 20.37-33.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Naba Alsaha Medical Services's full fundamentals live
Get Naba Alsaha Medical Services's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.